Exome sequencing of ATP1A3-negative cases of alternating hemiplegia of childhood reveals SCN2A as a novel causative gene

Eleni Panagiotakaki, Francesco D. Tiziano, Mohamad A. Mikati, Lisanne S. Vijfhuizen, Sophie Nicole, Gaetan Lesca, Emanuela Abiusi, Agnese Novelli, Lorena Di Pietro, Aster V.E. Harder, Nicole M. Walley, Elisa De Grandis, Anne Lise Poulat, Vincent Des Portes, Anne Lépine, Marie Cecile Nassogne, Alexis Arzimanoglou, Rosaria Vavassori, Jan Koenderink, Christopher H. ThompsonAlfred L. George, Fiorella Gurrieri, Arn M.J.M. van den Maagdenberg*, Erin L. Heinzen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Alternating hemiplegia of childhood (AHC) is a rare neurodevelopment disorder that is typically characterized by debilitating episodic attacks of hemiplegia, seizures, and intellectual disability. Over 85% of individuals with AHC have a de novo missense variant in ATP1A3 encoding the catalytic α3 subunit of neuronal Na+/K+ ATPases. The remainder of the patients are genetically unexplained. Here, we used next-generation sequencing to search for the genetic cause of 26 ATP1A3-negative index patients with a clinical presentation of AHC or an AHC-like phenotype. Three patients had affected siblings. Using targeted sequencing of exonic, intronic, and flanking regions of ATP1A3 in 22 of the 26 index patients, we found no ultra-rare variants. Using exome sequencing, we identified the likely genetic diagnosis in 9 probands (35%) in five genes, including RHOBTB2 (n = 3), ATP1A2 (n = 3), ANK3 (n = 1), SCN2A (n = 1), and CHD2 (n = 1). In follow-up investigations, two additional ATP1A3-negative individuals were found to have rare missense SCN2A variants, including one de novo likely pathogenic variant and one likely pathogenic variant for which inheritance could not be determined. Functional evaluation of the variants identified in SCN2A and ATP1A2 supports the pathogenicity of the identified variants. Our data show that genetic variants in various neurodevelopmental genes, including SCN2A, lead to AHC or AHC-like presentation. Still, the majority of ATP1A3-negative AHC or AHC-like patients remain unexplained, suggesting that other mutational mechanisms may account for the phenotype or that cases may be explained by oligo- or polygenic risk factors.

Original languageEnglish (US)
Pages (from-to)224-231
Number of pages8
JournalEuropean Journal of Human Genetics
Volume32
Issue number2
DOIs
StatePublished - Feb 2024

Funding

Genetic studies were funded in part by a grant from Cure AHC (ELH), AFM-Telethon, and AFHA (SN). Functional studies of SCN2A were supported by NIH grant NS108874 (ALG). The variant analysis of SCN2A Italian patients was supported by AISEA (FG, FDT). ALG serves on a scientific advisory board for Tevard Biosciences, and consults for Praxis Precision Medicines. ALG receives grant funding from Tevard Biosciences, Praxis Precision Medicines, and Neurocrine Biosciences for unrelated work. AMJMvdM received funding from Schedule 1 Therapeutics and Praxis Precision Medicines for unrelated work. The other authors declare no conflicts of interest.

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Exome sequencing of ATP1A3-negative cases of alternating hemiplegia of childhood reveals SCN2A as a novel causative gene'. Together they form a unique fingerprint.

Cite this